Multiple Sclerosis Center, Neurological Institute C Besta, Via Celoria, 11, 20133, Milan, Italy.
Neurol Sci. 2010 Jun;31(3):337-9. doi: 10.1007/s10072-009-0184-x. Epub 2009 Nov 19.
Previous reports have suggested an increased risk of psoriasis in MS patients. Worsening of dermatologic lesions during interferon therapy has been rarely reported, but activation of psoriatic arthritis has not been described until now. The following is a case report. A 37-year-old woman affected by relapsing-remitting multiple sclerosis had severe worsening of cutaneous psoriasis and activation of psoriatic arthritis during interferon beta treatment. The symptoms resolved after therapy discontinuation. This case further supports that activation of psoriasis might be a rare side effect of IFNB therapy and suggests careful evaluation of concomitant morbidity to allow a patient-oriented treatment strategy.
先前的报告表明多发性硬化症 (MS) 患者发生银屑病的风险增加。干扰素治疗期间皮肤损害恶化的情况很少见报道，但直到现在才描述了银屑病关节炎的激活。以下是一份病例报告。一名 37 岁女性，患有复发缓解型多发性硬化症，在接受干扰素 β 治疗期间出现严重的皮肤银屑病恶化和银屑病关节炎激活。停药后症状缓解。该病例进一步支持银屑病的激活可能是 IFNB 治疗的罕见副作用，并提示应仔细评估伴随疾病以制定以患者为中心的治疗策略。
